The rise of cardiac biomarkers due to planned PCI and 1-year prognosis in patients with stable coronary artery disease and arterial hypertension

Aim. The aim of our study was to assess the prevalence of myocardial infarction (MI) type 4a and myocardial damage due to planned percutaneous interventions (PCI) in patients with stable coronary artery disease (CAD) and arterial hypertension (AH).Material and methods. 281 patients were screened before the enrollment in our study. 183 patients with stable CAD were included in our study whose levels of cardiac troponin I and CK-MB (creatine kinase-MB fraction) were studied after PCI. We divided patients into the groups according to their levels of cardiac troponin I after PCI and CK-MB (group 1 - no elevation; 2 - elevation 1-3 upper limits of normal - ULN; III - more than 3 ULN).167 patients had AH. In case of detected rise of CK-MB and/or troponin echocardiography and cardiac magnetic resonance imaging (MRI) were performed. Results. The prevalence of MI type 4a was 10,8% and periprocedural myocardial damage - 16,2% respectively. After performing the discriminant analysis we sought to build a prognostic model and calculate the formula of periprocedural myocardial damage probability: 0,871 × gender (male = 0; female = 1)+0,516 × angina pectoris functional class + 0,022 × age (years) - 0,011 × (estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease - MDRD formula) + 0,27 × number of diseased coronary arteries ≥2,731.Conclusion. Women with low EGFR (MDRD), mutivessel disease and angina pectoris class 3-4 (NYHA) have the highest risk of MI type 4a. The most difficult localization for PCI is circumflex artery.

troponin, creatine kinase-MB, periprocedural myocardial infarction, myocardial infarction type 4a, myocardial infarction after percutane- ous interventions, arterial hypertension, percutaneous interventions, 1-year prognosis

1. Mozaffarain D, Benjamin E.J, Go A.S et al. Heart Disease And Stroke Statistics - 2015 Update. Circulation 2015; 131: e29-e322.

2. James P.A, Oparil S, Carter B.L et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507-20.

3. Chobanian A..V, Bakris G.L, Black H.R et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289 (19): 2560-71.

4. Kearney P.M, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.

5. Heidenreich P.A, Trogdon J.G, Khavjou O.A et al. On behalf of the American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123: 933-44.

6. Guo X, Zhang X, Guo L et al. Association between prehypertension and cardiovascular outcomes: a systematic review and meta - analysis of prospective studies. Curr Hypertens Rep 2013; 15: 703-16.

7. Murray C.J, Vos T, Lozano R et al. Disability - adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 [published correction appears in Lancet 2013; 381: 628]. Lancet 2012; 380: 2197-223.

8. Thygesen K, Alpert J.S, White H.D. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28: 2525-38; Circulation 2007; 116: 2634-53; J Am Coll Cardiol 2007; 50: 2173-95.

9. Nallamothu B.K, Chetcuti S, Mukherjee D et al. Prognostic implication of troponin I elevation after percutaneous coronary intervention. Am J Cardiol 2003; 91: 1272-74.

10. Fuchs S, Kornowski R, Mehran R et al. Prognostic value of cardiac troponin-I levels following catheter - based coronary interventions. Am J Cardiol 2000; 85: 1077-82.

11. Cavallini C, Savonitto S, Violini R et al. Impact of the elevation of biochemical markers of myocardial damage on long - term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J 2005; 26: 1494-98.

12. Миронова О.Ю. Индуцированная контрастными веществами нефропатия. Терапевт. арх. 2013; 85 (6): 90-5.

13. Kamugai S, Ishii H et al. Impact of chronic kidney disease on the incidence of periprocedural myocardial injury in patients undergoing elective stent implantation. Nephrol Dial Transplant 2012; 27 (3): 1059-63.

14. Miyagi M, Ishii H et al. Impact of renal function on coronary plaque composition. Nephrol Dial Transplant 2010; 25 (1): 175-81.

15. ESH/ESC Guidelines for the management of arterial hypertension Eur Heart J 2013; 34: 2159-19.

16. Berger A.K, Herzog C.A. CABG in CKD: untangling the letters of risk Nephrol Dial Transplant 2010; 25 (11): 3477-9.